Insulet Corporation on Focus After Bearish Options Activity

 Insulet Corporation on Focus After Bearish Options Activity

In today’s session Insulet Corporation (PODD) recorded an unusually high (282) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious PODD decrease. With 282 contracts traded and 4404 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: PODD161118P00035000 closed last at: $1.4 or 21.7% up. About 152,271 shares traded hands. Insulet Corporation (NASDAQ:PODD) has risen 6.30% since April 8, 2016 and is uptrending. It has outperformed by 0.66% the S&P500.

Insulet Corporation (NASDAQ:PODD) Ratings Coverage

Out of 9 analysts covering Insulet Corporation (NASDAQ:PODD), 5 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 56% are positive. Insulet Corporation has been the topic of 17 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Northland Capital maintained Insulet Corporation (NASDAQ:PODD) on Friday, November 6 with “Outperform” rating. The stock has “Equal-Weight” rating given by Morgan Stanley on Monday, November 2. The firm has “Outperform” rating given on Friday, April 29 by William Blair. The firm has “Buy” rating given on Friday, February 26 by Benchmark. Empire initiated it with “Sell” rating and $15 target price in Thursday, February 25 report. The rating was downgraded by Benchmark to “Hold” on Thursday, August 13. The company was maintained on Thursday, August 4 by Jefferies.

According to Zacks Investment Research, “INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company’s OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes.”

Insitutional Activity: The institutional sentiment increased to 1.35 in Q2 2016. Its up 0.43, from 0.92 in 2016Q1. The ratio increased, as 18 funds sold all Insulet Corporation shares owned while 45 reduced positions. 29 funds bought stakes while 56 increased positions. They now own 59.20 million shares or 0.11% less from 59.26 million shares in 2016Q1.
Clearbridge Llc last reported 0.07% of its portfolio in the stock. Royal Commercial Bank Of Canada has 1,315 shares for 0% of their US portfolio. Champlain Invest Prtn Limited Liability Corp has 950,235 shares for 0.5% of their US portfolio. Moreover, Research Glob has 0.05% invested in Insulet Corporation (NASDAQ:PODD) for 5.14 million shares. Prudential owns 15,002 shares or 0% of their US portfolio. Spark Invest Management Ltd Liability Com accumulated 0.15% or 54,300 shares. Bnp Paribas Arbitrage, a New York-based fund reported 3,691 shares. Moreover, Altrinsic Glob Advisors Ltd Co has 0.18% invested in Insulet Corporation (NASDAQ:PODD) for 210,900 shares. Nicholas Wi accumulated 0.02% or 35,085 shares. Amalgamated Financial Bank reported 6,094 shares or 0.02% of all its holdings. Rhumbline Advisers, a Massachusetts-based fund reported 73,685 shares. Shaker Invs Ltd Oh accumulated 2.02% or 73,540 shares. Panagora Asset last reported 11,591 shares in the company. Pnc Service Inc holds 0% of its portfolio in Insulet Corporation (NASDAQ:PODD) for 2,465 shares. Alliancebernstein Limited Partnership reported 99,711 shares or 0% of all its holdings.

Insider Transactions: Since May 13, 2016, the stock had 1 buy, and 1 sale for $971,259 net activity. SULLIVAN PATRICK J bought $1.22 million worth of stock. SOMMER REGINA O also sold $243,924 worth of Insulet Corporation (NASDAQ:PODD) on Wednesday, May 25. Thomas Bradley A bought $79,222 worth of Insulet Corporation (NASDAQ:PODD) on Friday, May 13.

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System , an insulin delivery system for people with insulin-dependent diabetes. The company has a market cap of $2.06 billion. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM). It currently has negative earnings. The Firm purchases OmniPods pursuant to its agreement with Flextronics.

PODD Company Profile

Insulet Corporation, incorporated on July 20, 2000, is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Company’s principal offices are located in Billerica, Massachusetts. The OmniPod System features two discreet devices and provides for automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Firm is producing the OmniPod on semi-automated manufacturing lines at a facility in China, operated by a subsidiary of Flextronics International Ltd. (Flextronics). The Firm purchases OmniPods pursuant to its agreement with Flextronics. It also partners with pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. It sells the OmniPod System and other diabetes management supplies in the United States through direct sales to clients or through its distribution partners. The OmniPod System is available in multiple countries in Europe, Canada and Israel.

More notable recent Insulet Corporation (NASDAQ:PODD) news were published by: which released: “Here’s Why Insulet Corporation Shares Are Surging 17.8% Today” on November 04, 2016, also with their article: “Why Insulet Corporation Shares Are Soaring 19.5% Today” published on August 04, 2016, published: “Why Insulet Corporation is Soaring Today” on February 26, 2016. More interesting news about Insulet Corporation (NASDAQ:PODD) were released by: and their article: “Why Insulet Corporation and Tandem Diabetes Care Both Tanked Today” published on May 03, 2016 as well as‘s news article titled: “Insulet Corporation to Announce Third Quarter 2016 Financial Results on …” with publication date: September 27, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment